This review highlights the paradoxical effects of aging on cardiac fibroblasts, where impaired reparative fibrosis and augmented interstitial fibrosis are driven by distinct signaling pathway alterations.
Answers are grounded in this paper and cite their sources.
Aging fibroblast changes may alter post-MI outcomes and interstitial fibrosis; leaves open age-specific therapeutic targeting pending translational studies.
The cardiac fibroblast plays a central role in tissue homeostasis and in repair after injury. With aging, dysregulated cardiac fibroblasts have a reduced capacity to activate a canonical transforming growth factor-β-Smad pathway and differentiate poorly into contractile myofibroblasts. That results in the formation of an insufficient scar after myocardial infarction. In contrast, in the uninjured aged heart, fibroblasts are activated and acquire a profibrotic phenotype that leads to interstitial fibrosis, ventricular stiffness, and diastolic dysfunction, all conditions that may lead to heart failure. There is an apparent paradox in aging, wherein reparative fibrosis is impaired but interstitial, adverse fibrosis is augmented. This could be explained by analyzing the effectiveness of signaling pathways in resident fibroblasts from young versus aged hearts. Whereas defective signaling by transforming growth factor-β leads to insufficient scar formation by myofibroblasts, enhanced activation of the ERK1/2 pathway may be responsible for interstitial fibrosis mediated by activated fibroblasts. Listen to this article's corresponding podcast at https://ajpheart.podbean.com/e/fibroblast-phenotypic-changes-in-the-aging-heart/ .
No takes yet. Share an insight, caveat, or question.
Trial et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: